(H02) HAW PAR - SG
Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: SG (Singapore) | Market Cap: 3.544m SGD | Total Return: 42.4% in 12m
Avg Turnover: 5.52M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Haw Par Corporation Limited is a Singapore-based conglomerate primarily recognized for its healthcare segment, which manufactures and distributes topical analgesics under the Tiger Balm and Kwan Loong brands. The company operates a diversified business model that includes property investment, the management of leisure attractions such as oceanariums, and the holding of a significant portfolio of quoted securities. In the pharmaceutical sector, topical analgesics are valued for their high brand loyalty and relatively low regulatory barriers compared to prescription drugs.
The company’s revenue streams are geographically diverse, spanning ASEAN nations, broader Asia, and international markets. Beyond its core healthcare operations, Haw Par generates recurring income through the leasing of commercial office spaces and investment properties. Investors looking for deeper insights into these diversified revenue segments may find ValueRays analytical tools useful for further due diligence. Historically, the company has maintained a strong balance sheet characterized by substantial strategic equity stakes in other major Singaporean financial and industrial entities.
- Tiger Balm sales growth driven by international expansion and tourism recovery
- Dividend income from UOB and UOL strategic equity holdings
- Rental income stability across Singapore and Malaysia investment property portfolio
- Healthcare segment margins impacted by raw material and marketing costs
| Net Income: 265.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 0.07 > 1.0 |
| NWC/Revenue: 1.81k% < 20% (prev 1.58k%; Δ 226.9% < -1%) |
| CFO/TA 0.01 > 3% & CFO 57.1m > Net Income 265.5m |
| Net Debt (-791.0m) to EBITDA (57.0m): -13.88 < 3 |
| Current Ratio: 52.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (221.4m) vs 12m ago 0.0% < -2% |
| Gross Margin: 55.99% > 18% (prev 54.77%; Δ 1.22% > 0.5%) |
| Asset Turnover: 5.29% > 50% (prev 5.72%; Δ -0.43% > 0%) |
| Interest Coverage Ratio: 33.23 > 6 (EBIT TTM 50.6m / Interest Expense TTM 1.52m) |
| A: 0.94 (Total Current Assets 4.25b - Total Current Liabilities 81.3m) / Total Assets 4.42b |
| B: 0.35 (Retained Earnings 1.53b / Total Assets 4.42b) |
| C: 0.01 (EBIT TTM 50.6m / Avg Total Assets 4.35b) |
| D: 33.83 (Book Value of Equity 4.29b / Total Liabilities 126.8m) |
| Altman-Z'' = 42.92 = AAA |
| DSRI: 0.75 (Receivables 33.8m/47.8m, Revenue 230.0m/244.8m) |
| GMI: 0.98 (GM 54.77% / 55.99%) |
| AQI: 0.53 (AQ_t 0.03 / AQ_t-1 0.05) |
| SGI: 0.94 (Revenue 230.0m / 244.8m) |
| TATA: 0.05 (NI 265.5m - CFO 57.1m) / TA 4.42b) |
| Beneish M = -3.56 (Cap -4..+1) = AAA |
As of June 20, 2026, the stock is trading at SGD 16.10 with a total of 376,400 shares traded.
Over the past week, the price has changed by +2.66%,
over one month by -2.46%,
over three months by +4.05% and
over the past year by +42.38%.
HAW PAR has no consensus analysts rating.
P/E Trailing = 13.3417
P/E Forward = 15.8228
P/S = 15.4114
P/B = 0.8342
Revenue TTM = 230.0m SGD
EBIT TTM = 50.6m SGD
EBITDA TTM = 57.0m SGD
Long Term Debt = 44.3m SGD (from longTermDebt, last quarter)
Short Term Debt = 44.3m SGD (from shortLongTermDebt, last quarter)
Debt = 422k SGD (Leases only: 422k)
Net Debt = -791.0m SGD (calculated: Debt 422k - CCE 791.4m)
Enterprise Value = 2.75b SGD (3.54b + Debt 422k - CCE 791.4m)
Interest Coverage Ratio = 33.23 (Ebit TTM 50.6m / Interest Expense TTM 1.52m)
EV/FCF = 50.05x (Enterprise Value 2.75b / FCF TTM 55.0m)
FCF Yield = 2.00% (FCF TTM 55.0m / Enterprise Value 2.75b)
FCF Margin = 23.92% (FCF TTM 55.0m / Revenue TTM 230.0m)
Net Margin = 115.4% (Net Income TTM 265.5m / Revenue TTM 230.0m)
Gross Margin = 55.99% ((Revenue TTM 230.0m - Cost of Revenue TTM 101.2m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.62 (Enterprise Value 2.75b / Total Assets 4.42b)
Interest Expense / Debt = 360.9% (Interest Expense 1.52m / Debt 422k)
Taxrate = 5.75% (16.2m / 281.6m)
NOPAT = 47.7m (EBIT 50.6m * (1 - 5.75%))
Current Ratio = 52.24 (Total Current Assets 4.25b / Total Current Liabilities 81.3m)
Debt / Equity = 0.00 (Debt 422k / totalStockholderEquity, last quarter 4.29b)
Debt / EBITDA = -13.88 (Net Debt -791.0m / EBITDA 57.0m)
Debt / FCF = -14.38 (Net Debt -791.0m / FCF TTM 55.0m)
Total Stockholder Equity = 4.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.11% (Net Income 265.5m / Total Assets 4.42b)
RoE = 6.55% (Net Income TTM 265.5m / Total Stockholder Equity 4.05b)
RoCE = 1.23% (EBIT 50.6m / Capital Employed (Equity 4.05b + L.T.Debt 44.3m))
RoIC = 1.10% (NOPAT 47.7m / Invested Capital 4.33b)
WACC = 6.47% (E(3.54b)/V(3.54b) * Re(6.47%) + (debt cost/tax rate unavailable))
Discount Rate = 6.47% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.41 | Cagr: 0.05%
[DCF] Terminal Value 76.58% ; FCFF base≈53.1m ; Y1≈57.5m ; Y5≈70.6m
[DCF] Fair Price = 8.46 (EV 1.08b - Net Debt -791.0m = Equity 1.87b / Shares 221.4m; r=8.35% [WACC [floored]]; 5y FCF grow 9.30% → 2.50% )
Revenue Correlation: -13.40 | Revenue CAGR: -0.45% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=1.25 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+4.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=1.28 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+2.8% | GrowthRev=+6.5%